why Esperion Therapeutics Inc. [ESPR] is a Good Choice for Investors After New Price Target of $11.36

Esperion Therapeutics Inc. [NASDAQ: ESPR] closed the trading session at $1.49 on 05/11/23. The day’s price range saw the stock hit a low of $1.43, while the highest price level was $1.60. The company report on May 9, 2023 at 7:00 AM that Esperion Reports First Quarter 2023 Financial Results.

– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million –.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


– Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q –.

The stocks have a year to date performance of -76.08 percent and weekly performance of 5.67 percent. The stock has been moved at -81.81 percent over the last six months. The stock has performed 15.50 percent around the most recent 30 days and changed -73.81 percent over the most recent 3-months.

If compared to the average trading volume of 4.21M shares, ESPR reached to a volume of 2555985 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Esperion Therapeutics Inc. [ESPR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $11.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Northland Capital have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Under Perform, with their previous recommendation back on March 16, 2023. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $8 to $1.50. The new note on the price target was released on March 16, 2023, representing the official price target for Esperion Therapeutics Inc. stock. Previously, the target price had yet another raise from $6.50 to $7, while Credit Suisse kept a Neutral rating on ESPR stock.

The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.17, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 1.77.

ESPR stock trade performance evaluation

Esperion Therapeutics Inc. [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.67. With this latest performance, ESPR shares gained by 15.50% in over the last four-week period, additionally sinking by -81.81% over the last 6 months – not to mention a drop of -70.96% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 44.89, with the RSI for the last a single of trading hit 59.00, and the three-weeks RSI is set at 37.31 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 2.1258, while it was recorded at 1.4240 for the last single week of trading, and 5.6829 for the last 200 days.

Esperion Therapeutics Inc. [ESPR]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc. [ESPR] shares currently have an operating margin of -237.83 and a Gross Margin at +63.61. Esperion Therapeutics Inc.’s Net Margin is presently recorded at -309.58.

Return on Total Capital for ESPR is now -71.65, given the latest momentum, and Return on Invested Capital for the company is -100.88. Additionally, ESPR Total Debt to Total Capital is recorded at 279.11, with Total Debt to Total Assets ending up at 203.50.

Reflecting on the efficiency of the workforce at the company, Esperion Therapeutics Inc. [ESPR] managed to generate an average of -$1,174,166 per employee. Receivables Turnover for the company is 2.66 with a Total Asset Turnover recorded at a value of 0.24.Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.70.

Earnings per share (EPS) analysis for Esperion Therapeutics Inc. [ESPR] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.

Esperion Therapeutics Inc. [ESPR]: Insider Ownership positions

There are presently around $108 million, or 87.80% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: WASATCH ADVISORS LP with ownership of 6,848,378, which is approximately -8.236% of the company’s market cap and around 0.60% of the total institutional ownership; BLACKROCK INC., holding 5,509,187 shares of the stock with an approximate value of $8.21 million in ESPR stocks shares; and MEDITOR GROUP LTD, currently with $6.56 million in ESPR stock with ownership of nearly -1.474% of the company’s market capitalization.

Positions in Esperion Therapeutics Inc. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 98 institutional holders increased their position in Esperion Therapeutics Inc. [NASDAQ:ESPR] by around 19,498,923 shares. Additionally, 79 investors decreased positions by around 12,338,221 shares, while 22 investors held positions by with 40,515,431 shares. The mentioned changes placed institutional holdings at 72,352,575 shares, according to the latest SEC report filing. ESPR stock had 42 new institutional investments in for a total of 9,677,223 shares, while 32 institutional investors sold positions of 4,858,787 shares during the same period.


Please enter your comment!
Please enter your name here